Skip to main content
. 2021 May 27;13:4233–4240. doi: 10.2147/CMAR.S304820

Figure 1.

Figure 1

Survival curves of all patients with advanced hepatocellular carcinoma who underwent lenvatinib plus camrelizumab treatment and lenvatinib monotherapy. (A) cumulative overall survival (OS) curves and, (B) cumulative progression-free survival (rPFS) curves.